CD19 and lupus nephritis: A double-target CAR T cell infusion harboring both BCMA (B cell maturation antigen) and CD19 molecules on CD19 B cells and plasma cells with BCMA surface antigen has been applied in patients with SLE and lupus nephritis in an open-label clinical trial [101].